Pacritinib Induced Reduction in Splenomegaly, Myelofibrosis Symptoms
The JAK2 and FLT3 inhibitor pacritinib induced significant and sustained spleen volume reduction and symptom reduction in patients with myelofibrosis.
Relapsed, Refractory Myeloma Has Indirect Societal Costs
Patients with relapsed or refractory multiple myeloma experienced significant indirect social costs from their disease, in addition to the direct costs.
Adjuvant TKI Use in High-Risk Clear Cell RCC Not Effective
Updated results of the ASSURE trial showed that adjuvant sunitinib or sorafenib did not improve disease-free survival among high-risk patients with renal cell carcinoma.
FDA Warns of Rare Cancer Linked to Breast Implants
The FDA has recently released a statement identifying a new rare T-cell lymphoma caused by breast implant surgery.
ASCO Statement Opposes Trump’s Recommended Budget Cuts to NIH
ASCO has released a statement announcing its opposition to President Trump’s budget outline for FY2018, which would cut about $6 billion in funding to the National Institutes of Health.
Short-Course RT With Delayed Surgery Viable in Rectal Cancer
No difference in time to recurrence, recurrence-free survival, or overall survival were noted for patients with rectal cancer who underwent one of three different preoperative radiotherapy regimens.
‘VCD-Lite’ Viable Option for Older, Toxicity-Vulnerable Myeloma Patients
Dose-attenuated bortezomib, cyclophosphamide, and dexamethasone (VCD-lite) is a viable treatment option for vulnerable or frail adults with newly diagnosed multiple myeloma.
Hodgkin Lymphoma Survivors at High Risk for Second Cancers
Patients who have survived Hodgkin lymphoma were at more than double the risk for diagnosis with a second cancer, according to the results of a recent study.
Adding Temozolomide to Short-Course RT Effective in Elderly Glioblastoma
Elderly patients with glioblastoma had longer survival when temozolomide was added to short-course radiotherapy compared with undergoing short-course radiotherapy alone.
Leucocyte Marker in Pediatric ALL Linked With Relapse-Free Survival
During maintenance therapy for childhood ALL, there was a general increase in DNA-incorporated thioguanine nucleotides (DNA-TGN), and this increase was associated with a lower frequency of disease relapse.
By clicking Accept, you agree to become a member of the UBM Medica Community.